The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability
Open accessAbstract
Individuals with hemizygous germline fumarate hydratase (FH) mutations are predisposed to renal cancer. These tumors predominantly exhibit functional inactivation of the remaining wild-type allele, implicating FH inactivation as a tumor-promoting event. Hypoxia-inducible factors are expressed in many cancers and are increased in clear cell renal carcinomas. Under normoxia, the HIFs are labile due to VHL-dependent proteasomal degradation, but stabilization occurs under hypoxia due to inactivation of HIF prolyl hydroxylase (HPH), which prevents HIF hydroxylation and VHL recognition. We demonstrate that FH inhibition, together with elevated intracellular fumarate, coincides with HIF upregulation. Further, we show that fumarate acts as a competitive inhibitor of HPH. These data delineate a novel fumarate-dependent pathway for regulating HPH activity and HIF protein levels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to requiring 2-oxoglutarate as a cosubstrate, the HIF hydroxylases have been reported to be inhibited by citrate, isocitrate, succinate, fumarate, malate, oxaloacetate, and pyruvate (Dalgard et al., 2004; Hewitson et al., 2007; Isaacs et al., 2005; Koivunen et al., 2007a; Selak et al., 2005).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Isaacs et al., 2005
In the citing paper
“To date, the clearest evidence that metabolites modulate HIF signaling comes from cells that are genetically defective in fumarate hydratase (FH) (Isaacs et al., 2005) or succinate hydrogenase (SDH; subunits b, c, and d) (MacKenzie et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Isaacs et al., 2005
In the citing paper
“Similar to succinate, fumarate contributes to the inactivation of PHD, stabilizing HIF proteins to promote cell survival133”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [133]
In the citing paper
“For example, the HIF1α transcription factor accumulates in SDH and FH mutant tumors, presumably due to inhibition of the EglN prolyl hydroxylases (Dahia et al., 2005; Isaacs et al., 2005; Pollard et al., 2005, 2007; Selak et al., 2005).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Isaacs et al., 2005
In the citing paper
“A similar model of substrate-mediated PHD inhibition has been described (23, 37, 42) in which the loss of fumarate hydratase activity leads to the accumulation of fumarate, which also can inhibit PHD competitively.”
From Loss of the SdhB, but Not the SdhA, Subunit of Complex II Triggers Reactive Oxygen Species-Dependent Hypoxia-Inducible Factor Activation and Tumorigenesis (2008) · cites this paper as [23]
In the citing paper
“PHDs are inactive at low O2 and can be inactivated by the accumulation of TCA metabolites fumarate and succinate, which may occur from mutations in the tumor suppressor genes succinate dehydrogenase subunit B or fumarate hydratase (187, 334, 384).”
From Redox regulation of mitochondrial function (2012) · cites this paper as [187]
In the citing paper
“In addition to affecting the activity of chromatin-associated αKG-dependent dioxygenases, succinate and fumarate accumulation can also inhibit αKG-dependent prolyl hydroxylases, leading to stabilization of HIF-1 and concomitant activation of the HIF/hypoxia transcriptional program (184, 185).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [184]
In the citing paper
“High levels of succinate and fumarate can inhibit PHD2 activity through product-mediated inhibition of PHD function, leading to HIF-1α protein stabilization under normoxic (20% O2) conditions (100, 101).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [100]
In the citing paper
“Subsequent work confirmed that fumarate could inhibit PHD2 (Isaacs et al., 2005)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Isaacs et al., 2005
In the citing paper
“elevated levels of succinate or fumarate can inhibit PHD activity [65, 66]”
From Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function (2013) · cites this paper as [65]
In the citing paper
“Both succinate and fumarate are competitive PHD inhibitors, and the massive accumulation of these metabolites in cells lacking SDH or FH activity elicit a hypoxic response even under oxygen-replete condition (Isaacs et al., 2005; Selak et al., 2005).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Isaacs et al., 2005
In the citing paper
“Furthermore, both succinate and fumarate aberrantly increase the function of hypoxia inducible factors (HIFs).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Isaacs et al., 2005
In the citing paper
“In the case of D2HGA, about 50% of patients present with D2HGDH mutations, while the remaining half possess mutations in the Krebs cycle enzyme isocitrate dehydrogenase 2 (IDH2), which converts isocitrate to α-KG110.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [110]
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
Self-citationThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Self-citationHIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Self-citationA conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Cellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476
(1999) · PubMed · Cited by 2,204
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108 · cited 3×
“Succinate also upregulates HIF by inhibiting its proline hydroxylation (Selak et al., 2005), but in vitro enzyme kinetic analysis proves it to be a weaker antagonist of 2-OG, a finding in keeping with its reduced potency (relative to fumarate) in causing intracellular HIF accumulation in A549 cells.”
BackgroundInfluential
Cited by
Sorted by citations
Items 401–500 of 957
MYBPC3 deficiency in cardiac fibroblasts drives their activation and contributes to fibrosis
Zou, X., Ouyang, H., Feng, L., Zhang, H., Yang, Y., Pang, D., Han, R., & Tang, X. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05403-6 · Cited by 46
Chakraborty, A. A., Nakamura, E., Qi, J., Creech, A. L., Jaffe, J. D., Paulk, J., Novak, J. S. S., Nagulapalli, K., McBrayer, S. K., Cowley, G. S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5272 · Cited by 45
Role of HIF1 α Regulatory Factors in Stem Cells
Lee, H. J., Jung, Y. H., Choi, G. E., Kim, J. S., Chae, C. W., & Han, H. J. (2019) · International Journal of Stem Cells · doi:10.15283/ijsc18109 · Cited by 45
Self-citationA New Specific Succinate-Glutamate Metabolomic Hallmark in Sdhx-Related Paragangliomas
Impériale, A., Moussallieh, F., Sebag, F. A., Brunaud, L., Barlier, A., Elbayed, K., Bachellier, P., Goichot, B., Pacák, K., Namer, I. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080539 · Cited by 43
Mitochondrial DNA and carcinogenesis (Review)
Grzybowska‐Szatkowska, L., & Ślaska, B. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.1027 · Cited by 43
Gambogic acid inhibits angiogenesis through inhibiting PHD2–VHL–HIF-1α pathway
Lu, N., Hui, H., Yang, H., Zhao, K., Chen, Y., You, Q., & Guo, Q. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.02.018 · Cited by 43
New treatment approaches in renal cell carcinoma
Facchini, G., Perri, F., Caraglia, M., Pisano, C., Striano, S., Marra, L., Fiore, F., Aprea, P., Pignata, S., & Iaffaioli, R. V. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32833123d4 · Cited by 44
Link between obesity and cancer: role of triglyceride/free fatty acid cycling.
Gong, Y., Lj, D., & Liang, J. (2014) · PubMed · Cited by 43
Analyzing Tumor Metabolism In Vivo
Faubert, B., & DeBerardinis, R. J. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-121954 · Cited by 44
Linehan, W. M., & Rathmell, W. K. (2012) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2012.08.021 · Cited by 43
Self-citationClinical and biochemical heterogeneity associated with fumarase deficiency
Ottolenghi, C., Hubert, L., Allanore, Y., Brassier, A., Altuzarra, C., Mellot‐Draznieks, C., Bekri, S., Goldenberg, A., Veyrieres, S., Boddaert, N., et al. (2011) · Human Mutation · doi:10.1002/humu.21534 · Cited by 43
Kawanaka, T., Kubo, A., Ikushima, H., Sano, T., Takegawa, Y., & Nishitani, H. (2008) · The Journal of Medical Investigation · doi:10.2152/jmi.55.78 · Cited by 45
Genetic causes of erythrocytosis and the oxygen-sensing pathway
Lee, F. S. (2008) · Blood Reviews · doi:10.1016/j.blre.2008.04.003 · Cited by 43
IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications
Choate, K. A., Pratt, E. P. S., Jennings, M. J., Winn, R. J., & Mann, P. B. (2024) · Biology · doi:10.3390/biology13110885 · Cited by 49
Linehan, W. M., Srinivasan, R., & Garcia, J. A. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.05.009 · Cited by 42
Self-citationInsights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas
Haake, S. M., Weyandt, J. D., & Rathmell, W. K. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0115 · Cited by 41
Bailey, P. S. J., & Nathan, J. A. (2018) · Biomedicines · doi:10.3390/biomedicines6020060 · Cited by 41
Johnson, T. I., Costa, A. S. H., Ferguson, A. N., & Frezza, C. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0912-3 · Cited by 40
Post-translational modifications of VDAC1 and VDAC2 cysteines from rat liver mitochondria
Saletti, R., Reina, S., Pittalà, M. G. G., Magrì, A., Cunsolo, V., Foti, S., & Pinto, V. D. (2018) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2018.06.007 · Cited by 40
Esser, T. U., Roshanbinfar, K., & Engel, F. B. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1561855 · Cited by 40
How DNA methylation affects the Warburg effect
Zhu, X., Xuan, Z., Chen, J., Li, Z., Zheng, S., & Song, P. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.45420 · Cited by 42
Rodrı́guez, C., Puente‐Moncada, N., Reiter, R. J., Sánchez‐Sánchez, A. M., Herrera, F., Rodríguez‐Blanco, J., Duarte‐Olivenza, C., Turos‐Cabal, M., Antolı́n, I., & Martı́n, V. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29886 · Cited by 40
The Role of Glucose Metabolism and Glucose-Associated Signalling in Cancer
Wittig, R., & Coy, J. F. (2007) · Perspectives in Medicinal Chemistry · doi:10.1177/1177391x0700100006 · Cited by 58
Lodi, A., & Ronen, S. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026155 · Cited by 41
Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer
Yuasa, T., Takahashi, S., Hatake, K., Yonese, J., & Fukui, I. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02054.x · Cited by 40
Miller, H. A., Yin, X., Smith, S. A., Hu, X., Zhang, X., Yan, J., Miller, D. M., van Berkel, V. H., & Frieboes, H. B. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.04.012 · Cited by 39
Protein networks linking Warburg and reverse Warburg effects to cancer cell metabolism
Johar, D., Elmehrath, A. O., Khalil, R. M., Elberry, M. H., Zaky, S., Shalabi, S. A., & Bernstein, L. H. (2021) · BioFactors · doi:10.1002/biof.1768 · Cited by 42
Familial Renal Cancer: Molecular Genetics and Surgical Management
Barrisford, G. W., Singer, E. A., Rosner, I. L., Linehan, W. M., & Bratslavsky, G. (2011) · International Journal of Surgical Oncology · doi:10.1155/2011/658767 · Cited by 40
Self-citationMetabolic Plasticity and Epithelial-Mesenchymal Transition
Thomson, T. M., Balcells, C. D., & Cascante, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070967 · Cited by 39
Zheng, L., Zhu, Z.-R., Sneh, T., Zhang, W.-T., Wang, Z.-Y., Wu, G., He, W., Qi, H., Wang, H., Wu, X., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165028 · Cited by 39
Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer
Srinivasan, R., Gurram, S., Singer, E. A., Sidana, A., Harthy, M. A., Ball, M. W., Friend, J. C., Mac, L. M., Purcell, E., Vocke, C. D., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2200900 · Cited by 39
Self-citationvan Spaendonck‐Zwarts, K. Y., Badeloe, S., Oosting, S. F., Hovenga, S., Semmelink, H. J. F., van Moorselaar, R. J. A., van Waesberghe, J. H., Mensenkamp, A. R., & Menko, F. H. (2011) · Familial Cancer · doi:10.1007/s10689-011-9491-5 · Cited by 37
Sankin, A. I., Hakimi, A. A., Hsieh, J. J.-D., & Molina, A. M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00067 · Cited by 38
Liang Cheng, C., Williamson, S. R., Zhang, S., MacLennan, G. T., Montironi, R., & Antonio Lopez-beltran, B. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.72 · Cited by 38
Tanaka, T., & Nangaku, M. (2009) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08r09fm · Cited by 38
Hypoxia signaling in the adipose tissue
Huynh, P. M., Wang, F., & An, Y. (2024) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjae039 · Cited by 42
Prolyl hydroxylase domain enzymes and their role in cell signaling and cancer metabolism
Nguyen, T.-L., & Durán, R. V. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.09.026 · Cited by 40
Targeting cancer's metabolic co-dependencies: A landscape shaped by genotype and tissue context
Bi, J., Wu, S., Zhang, W., & Mischel, P. S. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.05.002 · Cited by 37
Metabolic Drivers in Hereditary Cancer Syndromes
Sciacovelli, M., Schmidt, C., Maher, E. R., & Frezza, C. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033612 · Cited by 39
Ooi, A., & Furge, K. A. (2012) · 癌症：英文版 · doi:10.5732/cjc.012.10102 · Cited by 38
Regulated Function of the Prolyl-4-Hydroxylase Domain (PHD) Oxygen Sensor Proteins
Nytko, K. J., Spielmann, P., Camenisch, G., Wenger, R. H., & Stiehl, D. P. (2007) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.1683 · Cited by 37
Familial and Hereditary Renal Cancer Syndromes
Coleman, J. (2008) · Urologic Clinics of North America · doi:10.1016/j.ucl.2008.07.014 · Cited by 36
Yu, Y., Lu, Q., Chen, F., Wang, S., Niu, C., Liao, J., Wang, H., & Chen, F. (2022) · Food & Function · doi:10.1039/d1fo04396j · Cited by 36
Bock, K. D., Smet, F. D., de Oliveira, R. L., Anthonis, K., & Carmeliet, P. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0482-z · Cited by 39
Schaefer, I., Hornick, J. L., & Bovée, J. V. M. G. (2018) · Laboratory Investigation · doi:10.1038/s41374-017-0003-6 · Cited by 36
Genetics of Familial Renal Cancers
Maher, E. R. (2010) · Nephron Experimental Nephrology · doi:10.1159/000320892 · Cited by 35
Targeted therapies for non-clear renal cell carcinoma
Singer, E. A., Bratslavsky, G., Linehan, W. M., & Srinivasan, R. (2010) · Targeted Oncology · doi:10.1007/s11523-010-0148-3 · Cited by 35
Self-citationCurrent views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma
Vícha, A., Taïeb, D., & Pacák, K. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0398 · Cited by 35
Urayama, S. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i6.1707 · Cited by 36
Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
Wiele, A. J., Surasi, D. S., Rao, P., Sircar, K., Su, X., Bathala, T. K., Shah, A. Y., Jonasch, E. W., Cataldo, V. D., Genovese, G., et al. (2021) · Cancers · doi:10.3390/cancers13092170 · Cited by 34
Role of Mitochondrial Mutations in Cancer
Baysal, B. E. (2006) · Endocrine Pathology · doi:10.1385/ep:17:3:203 · Cited by 39
A common pathway for genetic events leading to pheochromocytoma
Maxwell, P. H. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.07.012 · Cited by 33
Han, J., Lee, J.-S., Choi, D., Lee, Y., Hong, S., Choi, J., Han, S.-Y., Ko, Y., Kim, J., & Kim, Y. M. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.01.003 · Cited by 34
Understanding hypoxia signalling in cells – a new therapeutic opportunity?
Ratcliffe, P. J. (2006) · Clinical Medicine · doi:10.7861/clinmedicine.6-6-573 · Cited by 33
Self-citationMaita, S., Yuasa, T., Tsuchiya, N., Mitobe, Y., Narita, S., Horikawa, Y., Hatake, K., Fukui, I., Kimura, S. H., Maekawa, T., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26034 · Cited by 32
Bardella, C., Olivero, M., Lorenzato, A., Geuna, M., Adam, J., O'Flaherty, L., Rustin, P., Tomlinson, I., Pollard, P. J., & Di Renzo, M. F. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06160-11 · Cited by 33
Altered Mitochondrial Signalling and Metabolism in Cancer
Chattopadhyay, E., & Roy, B. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00043 · Cited by 36
Macklin, P. S., Yamamoto, A., Browning, L., Hofer, M., Adam, J., & Pugh, C. W. (2020) · The Journal of Pathology · doi:10.1002/path.5402 · Cited by 33
Dorai, T., Sawczuk, I. S., Pastorek, J., Wiernik, P. H., & Dutcher, J. P. (2006) · Cancer Investigation · doi:10.1080/07357900601062321 · Cited by 33
Li, A. M., & Ye, J. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062822-120857 · Cited by 31
Oxygen Concentration Controls Epigenetic Effects in Models of Familial Paraganglioma
Her, Y. F., Nelson-Holte, M. H., & Maher, L. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127471 · Cited by 34
Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms
Yap, N. Y., Rajandram, R., Ng, K. L., Pailoor, J., Fadzli, A. N., & Gobe, G. C. (2015) · BioMed Research International · doi:10.1155/2015/476508 · Cited by 35
Metabolic modulation of cancer: a new frontier with great translational potential
Kinnaird, A. S., & Michelakis, E. D. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1250-2 · Cited by 32
Fumarase is involved in DNA double-strand break resection through a functional interaction with Sae2
Leshets, M., Ramamurthy, D., Lisby, M., Lehming, N., & Pines, O. (2017) · Current Genetics · doi:10.1007/s00294-017-0786-4 · Cited by 33
The PHD1 oxygen sensor in health and disease
Kennel, K. B., Burmeister, J., Schneider, M. A., & Taylor, C. T. (2018) · The Journal of Physiology · doi:10.1113/jp275327 · Cited by 34
Role of the KEAP1-NRF2 Axis in Renal Cell Carcinoma
Clerici, S., & Boletta, A. (2020) · Cancers · doi:10.3390/cancers12113458 · Cited by 36
Schlisio, S. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00881.x · Cited by 33
Koski, T. A., Lehtonen, H. J., Jee, K. J., Ninomiya, S., Joosse, S. A., Vahteristo, P., Kiuru, M. H., Karhu, A., Sammalkorpi, H., Vanharanta, S., et al. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20663 · Cited by 32
Robust metabolic adaptation underlying tumor progression
Vizán, P., Mazurek, S., & Cascante, M. (2008) · Metabolomics · doi:10.1007/s11306-007-0101-3 · Cited by 35
Everolimus – a new approach in the treatment of renal cell carcinoma
Eisen, T. G. (2010) · Cancer Management and Research · doi:10.2147/cmar.s6047 · Cited by 32
Verma, A. M. (2006) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000232895.28674.79 · Cited by 32
Post-translational regulation of metabolism in fumarate hydratase deficient cancer cells
Gonçalves, E., Sciacovelli, M., Costa, A. S. H., Tran, M. G. B., Johnson, T. I., Machado, D., Frezza, C., & Sáez-Rodríguez, J. (2017) · Metabolic Engineering · doi:10.1016/j.ymben.2017.11.011 · Cited by 31
Molecular Biology of Renal Cortical Tumors
Klatte, T., & Pantuck, A. J. (2008) · Urologic Clinics of North America · doi:10.1016/j.ucl.2008.07.006 · Cited by 31
Renal medullary carcinomas: histopathologic phenotype associated with diverse genotypes
Gatalica, Z., Lilleberg, S. L., Monzon, F. A., Koul, M. S., Bridge, J. A., Knezetic, J. A., Legendre, B. L., Sharma, P., & McCue, P. A. (2011) · Human Pathology · doi:10.1016/j.humpath.2011.02.026 · Cited by 31
Corrado, M., Scorrano, L., & Campello, S. (2016) · Oncotarget · doi:10.18632/oncotarget.8727 · Cited by 31
Vocke, C. D., Ricketts, C. J., Merino, M. J., Srinivasan, R., Metwalli, A. R., Middelton, L. A., Peterson, J. C., Yang, Y., & Linehan, W. M. (2017) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22452 · Cited by 31
Self-citationVerma, M., Kipari, T. M. J., Zhang, Z., Man, T. Y., Forster, T., Homer, N. Z. M., Seckl, J. R., Holmes, M. C., & Chapman, K. E. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.11.015 · Cited by 31
Park, H., Ohshima, K., Nojima, S., Tahara, S., Kurashige, M., Hori, Y., Okuzaki, D., Wada, N., Ikeda, J., & Morii, E. (2018) · Laboratory Investigation · doi:10.1038/s41374-017-0017-0 · Cited by 30
Tseng, P., Chen, C., Hu, K.-H., Cheng, H.-C., Lin, Y.-H., Tsai, W., Cheng, T., Wu, W.-H., Yeh, C., Lin, C.-C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24855 · Cited by 33
The metabolic landscape of urological cancers: New therapeutic perspectives
Miranda‐Gonçalves, V., Lameirinhas, A., Henrique, R., Baltazar, F., & Jerónimo, C. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.034 · Cited by 33
ROS production and angiogenic regulation by macrophages in response to heat therapy
Jackson, I. L., Jackson, I. L., Batinic-Haberle, I., Sonveaux, P., Dewhirst, M. W., & Vujaskovic, Z. (2006) · International Journal of Hyperthermia · doi:10.1080/02656730600594027 · Cited by 31
Hypoxia-inducible factors: Crosstalk between their protein stability and protein degradation
Wei, W., & Yu, X. D. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.08.009 · Cited by 33
Kuo, C., Cheng, C.-T., Hou, P., Lin, Y.-P., Ma, H., Chung, Y., Chi, K. K., Chen, Y., Li, W., Kung, H.-J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8570 · Cited by 32
Self-citationThe flux of energy in critical illness and the obesity paradox
Jaitovich, A., & Hall, J. B. (2025) · Physiological Reviews · doi:10.1152/physrev.00029.2024 · Cited by 34
Regulatory Roles of Metabolites in Cell Signaling Networks
Li, F., Xu, W., & Zhao, S. (2013) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2013.05.002 · Cited by 30
Zyla, R. E., & Hodgson, A. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207830 · Cited by 31
Trichonas, G., Lee, T. J., Hoppe, G., Au, J. D., & Sears, J. E. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-12171 · Cited by 31
Downregulation of SRF–FOS–JUNB pathway in fumarate hydratase deficiency and in uterine leiomyomas
Raimundo, N., Vanharanta, S., Aaltonen, L. A., Hovatta, I., & Suomalainen, A. (2009) · Oncogene · doi:10.1038/onc.2008.472 · Cited by 29
Hypoxia-inducible factor prolyl 4-hydroxylase inhibition in cardiometabolic diseases
Koivunen, P., Serpi, R., & Dimova, E. Y. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.003 · Cited by 33
Co-opting a Bioorthogonal Reaction for Oncometabolite Detection
Zengeya, T. T., Garlick, J. M., Kulkarni, R. A., Miley, M., Roberts, A. M., Yang, Y., Crooks, D. R., Sourbier, C., Linehan, W. M., & Meier, J. L. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b09706 · Cited by 30
Self-citationSchultz, K., Murthy, V., Tatro, J. B., & Beasley, D. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.90393.2008 · Cited by 32
Shen, T., Wang, H., Tang, B., Zhu, G., & Wang, X. (2023) · RNA Biology · doi:10.1080/15476286.2023.2216562 · Cited by 29
Luo, H., Wang, Q., Yang, F., Liu, R. R., Gao, Q., Cheng, B., Lin, X., Huang, L., Chen, C., Jin, X., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.164968 · Cited by 40
Conza, G. D., Cafarello, S. T., Zheng, X., Zhang, Q. H., & Mazzone, M. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.081 · Cited by 29
Lacking ketohexokinase-A exacerbates renal injury in streptozotocin-induced diabetic mice
Doke, T., Ishimoto, T., Hayasaki, T., Ikeda, S., Hasebe, M., Hirayama, A., Soga, T., Kato, N., Kosugi, T., Tsuboi, N., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2018.03.020 · Cited by 29
Oncometabolites and the response to radiotherapy
Xiang, K., Jendrossek, V., & Matschke, J. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01638-9 · Cited by 30
Precision Surgery and Kidney Cancer: Knowledge of Genetic Alterations Influences Surgical Management
Gomella, P. T., Linehan, W. M., & Ball, M. W. (2021) · Genes · doi:10.3390/genes12020261 · Cited by 30
Self-citationHypoxia-driven metabolic reprogramming of adipocytes fuels cancer cell proliferation
Aird, R., Wills, J. C., Roby, K. F., Bénézech, C., Stimson, R. H., Wabitsch, M., Pollard, J. W., Finch, A. J., & Michailidou, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.989523 · Cited by 29
Differential metabolic consequences of fumarate hydratase and respiratory chain defects
Raimundo, N., Ahtinen, J., Fumić, K., Barić, I., Remes, A. M., Renkonen, R., Lapatto, R., & Suomalainen, A. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.01.008 · Cited by 30
No evidence for a genetic modifier for renal cell cancer risk in HLRCC syndrome
Vahteristo, P., Koski, T. A., Näätsaari, L., Kiuru, M. H., Karhu, A., Herva, R., Sallinen, S., Kuismin, O., Björck, E., Richard, S., et al. (2009) · Familial Cancer · doi:10.1007/s10689-009-9312-2 · Cited by 29
Metadata
- Authors
- Isaacs, J. S., Jung, Y. J., Mole, D. R., Lee, S., Torres-Cabala, C., Chung, Y.-L., Merino, M., Trepel, J., Zbar, B., Toro, J., Ratcliffe, P. J., Linehan, W. M., & Neckers, L.
- Affiliations
- National Institutes of Health (US)
- Pusan National University (KR)
- University of Oxford (GB)
- National Cancer Institute (US)
- St George's Hospital (GB)
- Corresponding author
- Neckers, Len
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2005-08
- Volume
- 8
- Issue
- 2
- Pages
- 143-153
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2059747280
- Semantic Scholar
- 6906ef0c1fe45571640c3c7a6b3c9c2d9a979a64
- Cited by
- 958
- References
- 63
- Citations by year
- 2026: 26 · 2025: 30 · 2024: 30 · 2023: 36 · 2022: 45 · 2021: 37 · 2020: 46 · 2019: 40 · 2018: 50 · 2017: 40 · 2016: 44 · 2015: 64 · 2014: 54 · 2013: 60 · 2012: 64
- FWCI
- 14.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- fumarate hydratase, hypoxia-inducible factor, fumarate, HIF prolyl hydroxylase, competitive inhibition, clear cell renal cell carcinoma, biallelic loss, cancer susceptibility, hypoxia
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Adult, Alleles, Carcinoma, Renal Cell, DNA-Binding Proteins, Female, Fumarate Hydratase, Fumarates, Humans, Ketoglutaric Acids, Kidney Neoplasms, Male, Middle Aged, Nuclear Proteins, Procollagen-Proline Dioxygenase, Syndrome, Transcription Factors, Up-Regulation, Gene Expression Regulation, Neoplastic, Leiomyomatosis, Basic Helix-Loop-Helix Proteins, Basic Helix-Loop-Helix Transcription Factors, Hypoxia-Inducible Factor 1, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
